Dainippon Sumitomo Rolls Out Latuda; Will Sepracor's $2.6 Billion Sales Force Pay Off?
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Dainippon Sumitomo launched its atypical antipsychotic Latuda (lurasidone) in the U.S. Feb. 4, and now the pressure is on to capitalize on the sales force it acquired in the acquisition of Sepracor. Analysts' eyes will be on Latuda's initial sales to gauge the company's acquired ability to market its in-house drugs in the U.S
You may also be interested in...
New Indications For Sunovion’s Latuda Mean New Marketing Strategy
The Japanese pharma gained two more indications for the atypical antipsychotic and hopes to differentiate it by stressing its approval as both a monotherapy and adjunctive therapy to standards of care.
Dainippon Buys Boston Biomedical To Build On Cancer Strategy
Japanese pharma Dainippon will gain two clinical-stage novel drugs targeting cancer stem cells and a drug-discovery platform with the acquisition of Boston Biomedical for $200 million upfront and substantial milestones.
Dainippon Buys Boston Biomedical To Build On Cancer Strategy
Japanese pharma Dainippon will gain two clinical-stage novel drugs targeting cancer stem cells and a drug-discovery platform with the acquisition of Boston Biomedical for $200 million upfront and substantial milestones.